Most Popular

1
1 in 3 Koreans live alone, family types becoming diverse
2
Korea, Japan finance chiefs vow to tame rampant FX market volatility
3
K-pop singer lost consciousness after being hit by foul ball, cancels show
4
K-pop group's manager dismissed for setting up spycam in theater dressing room
5
Contentious grain bill put directly to plenary meeting for vote

6
Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
7
Why is Apple Pay struggling to get purchase in Korea?
8
Yoon's office denies considering liberal figures for key posts
9
Trilateral talks acknowledge ‘serious’ slumps of won, yen
10
[Today’s K-pop] BTS pop-up event to come to Seoul

NewsletterSubscribe

Start your day with a roundup of key stories from The Korea Herald with news and comment on all that’s happening in Korea.

Genexine’s COVID-19 drug to begin phase 1 trial in Korea

By Lim Jeong-yeo

Published : Aug. 7, 2020 - 18:09

- Link copied

Genexine‘s COVID-19 treatment candidate GX-17 was given the Korean drug authority’s grant to proceed to phase 1 human trials, Friday.

GX-17 is a protein drug recombining human IL-7 and hybrid Fc (hyFc) that the company had been developing as an anti-cancer treatment. It is a T-Cell growth factor that proliferates a patient‘s immune cells, by which it slows the progression of an illness and hastens recovery.

With the addition of GX-17, South Korea now has 13 treatment researches and two vaccine researches ongoing to tackle COVID-19.

By Lim Jeong-yeo (kaylalim@heraldcorp.com)

Genexine’s COVID-19 drug to begin phase 1 trial in Korea

More from Headlines